Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1985 Dec;20(3):198–204. doi: 10.1007/BF00205576

Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells

Mario P Colombo 1, Mariella Parenza 1, Giorgio Parmiani 1
PMCID: PMC11038803  PMID: 3851699

Abstract

It has been previously shown that the BALB/c lymphoma YC8 is susceptible to lysis by syngeneic anti-DBA/2 lymphocytes and that YC8-bearing BALB/c mice can be cured by adoptive transfer of such immune effectors. In this study in vivo and in vitro functions of the curative immune lymphocytes have been evaluated together with the role of the host immune system in the mechanism of tumor eradication. It was found that the curative anti-DBA/2 lymphocytes were not directly cytotoxic to YC8 cells although they developed into YC8-lytic cells after in vitro restimulation with YC8. In vivo, the immune lymphocytes were able to mediate a tumor-specific delayed type hypersensitivity reaction against YC8 but had a low tumor-neutralizing activity in the Winn assay. Proliferation of infused BALB/c anti-DBA/2 lymphocytes was necessary for the in vivo therapeutic effect, since irradiation of effector cells or treatment of the donor immune lymphocytes with vinblastine abolished their curative capacity. Immunodepression of the T cell compartment of the prospective tumor-bearing animals by thymectomy plus irradiation or its abrogation in B mice (thymectomized, lethally irradiated, and reconstituted with fetal liver cells) did not interfere with the therapeutic effect of the transferred anti-DBA/2 lymphocytes. Blocking the macrophage functions of the host by carrageenan, however, abolished the therapeutic effect of immune lymphocytes. These data indicate that a radiation-resistant, non-T cell is involved in the tumor eradication induced by anti-DBA/2 lymphocytes. It was also shown that cured mice, tested 90 days after therapy, become resistant to 5×103 LD80 YC8 cells and that this resistance was due to the presence of memory cells derived from the transferred and not from the host lymphocyte population.

Keywords: Lymphoma, Vinblastine, Fetal Liver, Adoptive Transfer, Host Immune System

References

  • 1.Balsari A, Fossati G, Taramelli D, Nava M, Ravagnani F, Parmiani G. Inhibition of human melanoma growth in nude mice by autologous alloactivated peripheral blood lymphocytes. Tumori. 1984;70:35. doi: 10.1177/030089168407000106. [DOI] [PubMed] [Google Scholar]
  • 2.Berendt MJ, North RJ. T-cell mediated suppression of antitumor immunity. An explanation for the progressive growth of an immunogenic tumor. J Exp Med. 1980;151:69. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Boon T. Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res. 1983;39:121. doi: 10.1016/s0065-230x(08)61034-9. [DOI] [PubMed] [Google Scholar]
  • 4.Cheever MA, Greenberg PD, Fefer A. Potential for specific cancer therapy with immune T lymphocytes. J Biol Response Mod. 1984;3:113. [PubMed] [Google Scholar]
  • 5.Colombo MP, Arioli I, Parmiani G. Passive adoptive immunotherapy of a low immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes. Int J Cancer. 1984;34:807. doi: 10.1002/ijc.2910340611. [DOI] [PubMed] [Google Scholar]
  • 6.Dennis JW, Leferté S, Man MS, Elliott BE, Kerbel RS. Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines. Int J Cancer. 1984;34:709. doi: 10.1002/ijc.2910340519. [DOI] [PubMed] [Google Scholar]
  • 7.Engers HD, Lahaye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner KT. Functional activity in vivo of effector T cell populations. II. Antitumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. J Immunol. 1984;133:1664. [PubMed] [Google Scholar]
  • 8.Fefer A. Adoptive chemoimmunotherapy of a Moloney lymphoma. Int J Cancer. 1971;8:364. doi: 10.1002/ijc.2910080303. [DOI] [PubMed] [Google Scholar]
  • 9.Fernandez-Cruz E, Gilman SC, Feldman JD. Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T-cell subset and nature of suppression. J Immunol. 1982;128:1112. [PubMed] [Google Scholar]
  • 10.Fossati G, Balsari A, Taramelli D, Sensi ML, Pellegris G, Nava M, Parmiani G. Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. Cancer Immunol Immunother. 1982;14:99. doi: 10.1007/BF00200176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fujiwara H, Haoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T. Establishment of a tumor specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochtonous tumor system. J Immunol. 1984;133:509. [PubMed] [Google Scholar]
  • 12.Greenberg PD, Cheever MA. Treatment of disseminate leukemia with cyclophosphamide and immune cells; Tumor immunity reflects long-term persistance of tumor-specific donor T cells. J Immunol. 1984;133:3401. [PubMed] [Google Scholar]
  • 13.Greenberg PD, Cheever MA, Fefer A. Eradication of disseminate murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt 1+2− lymphocytes. J Exp Med. 1981;154:952. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells. J Exp Med. 1983;157:884. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hewitt HB. A critical examination of the foundations of immunotherapy for cancer. Clin Radiol. 1979;30:361. doi: 10.1016/s0009-9260(79)80209-3. [DOI] [PubMed] [Google Scholar]
  • 16.Huber B, Devinsky O, Gershon RK, Cantor H. Cell-mediated immunity: Delayed type hypersensitivity and cytotoxic response are mediated by different T-cell sublcasses. J Exp Med. 1976;143:1534. doi: 10.1084/jem.143.6.1534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Leshen B, Gotsman B, Kedar E. In vitro elicitation of cytotoxic response against a non-immunogenic murine tumor by allosensitization. Cancer Immunol Immunother. 1984;17:117. doi: 10.1007/BF00200047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mac Phail S, Paciucci A, Stutman O. Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactions. J Immunol. 1984;132:3205. [PubMed] [Google Scholar]
  • 19.Mazumder A, Rosenberg SA. Successful immunotherapy by natural kller-resistant established pulmonary melanoma metastases by intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984;159:495. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science. 1984;225:1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  • 21.Paciucci PA, MacPhail S, Zarling JM, Bach FH. Lysis of syngeneic solid tumor cells by alloantigens stimulated mouse T and non-T cells. J Immunol. 1980;124:370. [PubMed] [Google Scholar]
  • 22.Parmiani G, Sensi ML, Carbone G, Colombo MP, Pierotti MP, Ballinari D, Hilgers J, Hilkens J. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. Int J Cancer. 1982;29:323. doi: 10.1002/ijc.2910290316. [DOI] [PubMed] [Google Scholar]
  • 23.Perry L, Greene MI. T cell subset interactions in the regulation of syngeneic tumor immunity. Fed Proc. 1981;40:39. [PubMed] [Google Scholar]
  • 24.Sensi ML, Parenza M, Parmiani G. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. J Natl Cancer Inst. 1983;70:291. [PubMed] [Google Scholar]
  • 25.Sensi ML, Orosz CG, Bach FH. Alloantigens induced cytotoxicity against syngeneic tumor cells. Analysis at the clonal level. J Immunol. 1984;132:3218. [PubMed] [Google Scholar]
  • 26.Shu S, Fonseca LS, Hunter JT, Rapp HJ. Mechanism of immunological eradication of a syngeneic guinea pig tumor. II. Effect of methotrexate treatment and T cell depletion of the recipient on adoptive immunity. Transplantation. 1983;35:56. doi: 10.1097/00007890-198301000-00011. [DOI] [PubMed] [Google Scholar]
  • 27.Shu S, Fonseca LS, Kato H, Zbar B. Mechanism of immunological eradication of a syngeneic guinea pig tumor: participation of a compartent(s) of recipient origins in the expression of systemic adoptive immunity. Cancer Res. 1983;43:2637. [PubMed] [Google Scholar]
  • 28.Strausser JL, Mazumder A, Grimm EA, Lotze MT, Rosenberg SA. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol. 1981;127:266. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES